Varian Medical Systems Aktie
WKN: 852812 ISIN: US92220P1057
aktueller Kurs:
148,00 EUR
0,00 EUR
Veränderung in %:
0,00 %
weitere Analysen einblenden

Varian Expects to Benefit from the Extension of Medical Linear Accelerators Tariff Exclusion in China

Mittwoch, 16.09.20 14:15
Bildquelle: Fotolia

PR Newswire

PALO ALTO, Calif. and BEIJING, Sept. 16, 2020 /PRNewswire/ -- Varian (NYSE: VAR) has received notice from the Customs Tariff Commission of the State Council of China that the first exclusion of the additional tariffs China imposed on US products will expire on September 16, 2020. In accordance with procedures, the exclusion will be extended by one year, from September 17, 2020 to September 16, 2021. Varian medical linear accelerators are one of the first items to be excluded from additional tariffs.

"We are grateful for the extension. It demonstrates China government's determination to fight cancer and its recognition of the positive impact of radiotherapy treatments," said Dow Wilson, chief executive officer of Varian. "Together, we can develop and provide a more intelligent cancer care solutions to accelerate our pace toward the vision of a world without fear of cancer. The extension of exemption allows us to continue to focus on the fight against cancer."

About Varian

At Varian, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 10,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit and follow @VarianMedSys on Twitter.

Press Contacts

Aimee Corso

Health + Commerce

+1 (310) 780-2661

Investor Relations Contact

Anshul Maheshwari

Vice President, Investor Relations

+1 (650) 424-5631

Cision View original content:


Quelle: PR Newswire

Hier geht's zur Aktien-Startseite

News und Analysen

Lifshitz Law Firm, P.C. Announces Investigation of Akcea Therapeutics, Inc. (NASDAQ: AKCA), BMC Stock Holdings, Inc. (NASDAQ: BMCH), Builders FirstSource, Inc. (NASDAQ: BLDR), Cancer Genetics, Inc. (N

PR NewswireNEW YORK, Sept. 25, 2020NEW YORK, Sept. 25, 2020 /PRNewswire/ --Akcea Therapeutics, Inc. (NASDAQ: AKCA)Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary ...weiterlesen

Seite: 1 | 2 | 3 | 4 | 5 | 6 | ►


Im Fokus

Aktueller Chart
  • +370% Kursgewinn seit Jahresstart!
  • Explodiert die Tesla-Aktie wieder?
  • Jetzt gratis Tesla-Report downloaden!


Value oder Growth? Eine Frage so alt wie die Börse

Value oder Growth? Eine Frage so alt wie die Börse
Die Frage, ob es sinnvoller ist, auf Value- oder auf Growth-Titel zu setzen, ist beinahe so alt wie die Börse selbst. Dabei sind mit der Bezeichnung „Value“ bewährte Unternehmen gemeint, deren Buchwert idealerweise aktuell möglichst niedrig bewertet wird.
© 1994-2020 by - Quelle für Kurse und Daten: ARIVA.DE AG - übernimmt keine Gewähr